Collegium Pharmaceutical
COLL
eBay
EBAY
Halozyme Therapeutics
HALO
SilverCrest Metals
SILV
Workday
WDAY
(FY)Mar 31, 2024 | (FY)Mar 31, 2023 | (FY)Mar 31, 2022 | (FY)Mar 31, 2021 | (FY)Mar 31, 2020 | (FY)Mar 31, 2019 | (FY)Mar 31, 2018 | (FY)Mar 31, 2017 | (FY)Mar 31, 2016 | (FY)Mar 31, 2015 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 9.22%3.17B | 85.91%2.91B | 82.05%1.56B | -23.70%858.42M | 44.84%1.12B | 21.86%776.71M | 98.00%637.36M | 105.42%321.89M | 1,178.25%156.7M | 2,361.65%12.26M |
Operating revenue | 9.22%3.17B | 85.91%2.91B | 82.05%1.56B | -23.70%858.42M | 44.84%1.12B | 21.86%776.71M | 98.00%637.36M | 105.42%321.89M | 1,178.25%156.7M | 2,361.65%12.26M |
Cost of revenue | 9.13%1.99B | 92.01%1.82B | 72.49%947.97M | -14.89%549.58M | 46.46%645.76M | 36.87%440.91M | 62.30%322.14M | 42.06%198.48M | 47.76%139.72M | 1,941.41%94.56M |
Gross profit | 9.38%1.19B | 76.51%1.09B | 99.05%614.75M | -35.56%308.84M | 42.72%479.24M | 6.53%335.8M | 155.43%315.23M | 626.63%123.41M | 120.64%16.98M | -1,890.78%-82.3M |
Operating expense | 38.60%324.01M | 46.65%233.77M | 5.50%159.4M | -8.96%151.1M | 26.72%165.97M | -8.12%130.98M | 55.88%142.56M | -35.50%91.46M | 15.30%141.79M | -31.17%122.97M |
Selling and administrative expenses | 38.72%329.94M | 45.76%237.85M | 3.61%163.18M | -6.91%157.49M | 27.67%169.18M | -8.00%132.51M | 42.77%144.03M | -30.62%100.88M | 16.42%145.4M | -30.17%124.89M |
-General and administrative expense | 38.72%329.94M | 45.76%237.85M | 3.61%163.18M | -6.91%157.49M | 27.67%169.18M | -8.00%132.51M | 42.77%144.03M | -30.62%100.88M | 16.42%145.4M | -30.17%124.89M |
Operating profit | 1.36%862.88M | 86.96%851.33M | 188.66%455.35M | -49.65%157.74M | 52.95%313.27M | 18.62%204.82M | 440.39%172.66M | 125.60%31.95M | 39.20%-124.8M | -12.29%-205.27M |
Net non-operating interest income expense | -9.48%-654.97M | -10.18%-598.25M | -10.58%-542.96M | 38.62%-491.02M | -9.02%-800.04M | -17.22%-733.83M | -19.28%-626.05M | -21.15%-524.87M | -75.39%-433.26M | 34.15%-247.02M |
Non-operating interest income | -6.28%895K | 133.50%955K | 102.48%409K | -68.58%202K | -55.29%643K | 284.49%1.44M | 236.94%374K | 3.74%111K | -53.28%107K | 61.27%229K |
Non-operating interest expense | 9.46%655.86M | 10.28%599.21M | 10.61%543.37M | -38.65%491.23M | 8.90%800.68M | 17.38%735.26M | 19.32%626.42M | 21.14%524.98M | 75.27%433.36M | -34.11%247.25M |
Other net income (expense) | ||||||||||
Special income (charges) | 179.65%1.08B | -225.76%-1.36B | -137.29%-418.08M | 29.61%1.12B | 102.01%865.11M | 268.09%428.25M | 1,316.93%116.34M | 101.20%8.21M | 90.37%-686.86M | -2,073.23%-7.14B |
-Less:Impairment of capital assets | -180.17%-1.09B | 226.48%1.36B | 137.18%416.84M | -89.25%-1.12B | -37.85%-592.33M | -268.86%-429.68M | -728,156.25%-116.49M | -100.00%16K | -90.36%683.03M | 2,626.84%7.09B |
-Less:Other special charges | -57.59%-301K | -19,000.00%-191K | 96.55%-1K | 99.99%-29K | -323,246.43%-271.44M | 282.61%84K | 80.09%-46K | 60.51%-231K | -1,460.47%-585K | -99.92%43K |
-Write off | 420.48%6.48M | 0.32%1.25M | 639.57%1.24M | 82.77%-230K | -199.04%-1.34M | 605.76%1.35M | 102.39%191K | -281.15%-8M | -91.17%4.41M | 291.17%50.01M |
Other non- operating income (expenses) | -42.67%6.58M | 53.68%11.48M | -90.08%7.47M | 2,876.32%75.3M | 562.30%2.53M | 149.16%382K | -172.48%-777K | 115.12%1.07M | 68.63%-7.09M | 89.72%-22.6M |
Income before tax | 261.67%2.21B | -345.98%-1.37B | -116.87%-307.07M | 19.69%1.82B | 2,483.33%1.52B | 55.99%-63.83M | 29.21%-145.01M | 62.99%-204.85M | 91.94%-553.46M | -561.58%-6.87B |
Income tax | 129.46%536.12M | 456.52%233.64M | 64.15%41.98M | -67.72%25.58M | 508.37%79.22M | -229.99%-19.4M | 14.92M | 0 | 0 | 0 |
Net income | 204.67%1.68B | -359.27%-1.6B | -119.44%-349.05M | 24.49%1.8B | 3,345.78%1.44B | 72.22%-44.43M | 21.92%-159.94M | 62.99%-204.85M | 91.94%-553.46M | -561.58%-6.87B |
Net income continuous Operations | 204.67%1.68B | -359.27%-1.6B | -119.44%-349.05M | 24.49%1.8B | 3,345.78%1.44B | 72.22%-44.43M | 21.92%-159.94M | 62.99%-204.85M | 91.94%-553.46M | -561.58%-6.87B |
Minority interest income | ||||||||||
Net income attributable to the parent company | 204.67%1.68B | -359.27%-1.6B | -119.44%-349.05M | 24.49%1.8B | 3,345.78%1.44B | 72.22%-44.43M | 21.92%-159.94M | 62.99%-204.85M | 91.94%-553.46M | -561.58%-6.87B |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 204.67%1.68B | -359.27%-1.6B | -119.44%-349.05M | 24.49%1.8B | 3,345.78%1.44B | 72.22%-44.43M | 21.92%-159.94M | 62.99%-204.85M | 91.94%-553.46M | -561.58%-6.87B |
Basic earnings per share | 204.69%44.6 | -358.06%-42.6 | -119.50%-9.3 | 24.54%47.7 | 3,291.67%38.3 | 73.33%-1.2 | 18.18%-4.5 | 65.63%-5.5 | 92.14%-16 | -567.21%-203.5 |
Diluted earnings per share | 204.69%44.6 | -358.06%-42.6 | -602.70%-9.3 | 146.67%1.85 | 162.50%0.75 | 73.33%-1.2 | 18.18%-4.5 | 65.63%-5.5 | 92.14%-16 | -567.21%-203.5 |
Dividend per share | ||||||||||
Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |